Upsher-Smith launches generic Rozerem

Upsher-Smith is introducing ramelteon tablets in a dosage strength of 8 mg.

The medication is the generic of Takeda’s Rozerem.

It is indicated for the treatment of insomnia characterized by difficulty with sleep onset.

"Expanding Upsher-Smith's portfolio of generic drug products and providing patients access to affordable generic medicines continues to be a priority," said Rusty Field, president and CEO, Upsher-Smith. "The launch of ramelteon, the company's sixth generic product launch this year, clearly demonstrates the incredible resolve of our team in helping achieve these milestones during an unprecedented time."

Ramelteon had a market value of approximately $26 million for the 12 months ended October 2020, according to IQVIA.